WBR0642: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
Line 20: | Line 20: | ||
|MainCategory=Microbiology, Pharmacology | |MainCategory=Microbiology, Pharmacology | ||
|SubCategory=Infectious Disease | |SubCategory=Infectious Disease | ||
|Prompt=A pharmaceutical company is trying to develop a new antibiotic to overcome increasing resistance to macrolides. | |Prompt=A pharmaceutical company is trying to develop a new antibiotic to overcome increasing resistance to macrolides. Its rationale is to create an agent that would be co-administered with azithromycin that counteracts the mechanism by which bacteria become resistant to this antibiotic. Which of the following agents would be appropriate to investigate for this purpose? | ||
|Explanation=[[Image:Resistance_mechanisms.png | 700px]] | |Explanation=[[Image:Resistance_mechanisms.png | 700px]] | ||
Line 39: | Line 39: | ||
|AnswerCExp=Beta-lactamase inhibitors like tazobactam, clavulanic acid, and sulbactam are used with penicillin antibiotics to inhibit destruction of the beta-lactam ring by beta-lactamase producing bacteria. | |AnswerCExp=Beta-lactamase inhibitors like tazobactam, clavulanic acid, and sulbactam are used with penicillin antibiotics to inhibit destruction of the beta-lactam ring by beta-lactamase producing bacteria. | ||
|AnswerD=Drug efflux pump blockers | |AnswerD=Drug efflux pump blockers | ||
|AnswerDExp=Although drug efflux can be seen as a mechanism of resistance to macrolides, it is minor compared to rRNA methylation. | |AnswerDExp=Although drug efflux can be seen as a mechanism of resistance to macrolides, it is minor compared to rRNA methylation. | ||
|AnswerE=Drug adenylation inhibitors | |AnswerE=Drug adenylation inhibitors | ||
|AnswerEExp=Drug adenylation is also a form of enzymatic modification seen in resistance to aminoglycosides not in macrolides. | |AnswerEExp=Drug adenylation is also a form of enzymatic modification seen in resistance to aminoglycosides not in macrolides. |
Revision as of 17:27, 23 October 2013
Author | [[PageAuthor::Rim Halaby, M.D. [1]]] |
---|---|
Exam Type | ExamType::USMLE Step 1 |
Main Category | MainCategory::Microbiology, MainCategory::Pharmacology |
Sub Category | SubCategory::Infectious Disease |
Prompt | [[Prompt::A pharmaceutical company is trying to develop a new antibiotic to overcome increasing resistance to macrolides. Its rationale is to create an agent that would be co-administered with azithromycin that counteracts the mechanism by which bacteria become resistant to this antibiotic. Which of the following agents would be appropriate to investigate for this purpose?]] |
Answer A | AnswerA::RNA methylation inhibitors |
Answer A Explanation | AnswerAExp::Inhibition of RNA methylation can in theory help decrease resistance to macrolides since it targets the main resistance mechanism. |
Answer B | AnswerB::Drug acetylation inhibitors |
Answer B Explanation | AnswerBExp::Acetylation inhibitors would work more for aminoglycoside resistance but not for macrolides |
Answer C | AnswerC::Beta-lactamase inhibitors |
Answer C Explanation | AnswerCExp::Beta-lactamase inhibitors like tazobactam, clavulanic acid, and sulbactam are used with penicillin antibiotics to inhibit destruction of the beta-lactam ring by beta-lactamase producing bacteria. |
Answer D | AnswerD::Drug efflux pump blockers |
Answer D Explanation | AnswerDExp::Although drug efflux can be seen as a mechanism of resistance to macrolides, it is minor compared to rRNA methylation. |
Answer E | AnswerE::Drug adenylation inhibitors |
Answer E Explanation | AnswerEExp::Drug adenylation is also a form of enzymatic modification seen in resistance to aminoglycosides not in macrolides. |
Right Answer | RightAnswer::A |
Explanation | [[Explanation::
|
Approved | Approved::No |
Keyword | WBRKeyword::Antibiotic resistance, WBRKeyword::Macrolides |
Linked Question | Linked:: |
Order in Linked Questions | LinkedOrder:: |